Citations (25)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Amanda K Irish, Constance M Erickson, Terry L Wahls, Linda G Snetselaar & Warren G Darling. (2017) Randomized control trial evaluation of a modified Paleolithic dietary intervention in the treatment of relapsing-remitting multiple sclerosis: a pilot study. Degenerative Neurological and Neuromuscular Disease 7, pages 1-18.
Read now
Read now
Ceri J Phillips & Ioan Humphreys. (2009) Assessing cost-effectiveness in the management of multiple sclerosis. ClinicoEconomics and Outcomes Research 1, pages 61-78.
Read now
Read now
Jeffrey S Hoch. (2004) Cost-effectiveness lessons from disease-modifying drugs in the treatment of multiple sclerosis. Expert Review of Pharmacoeconomics & Outcomes Research 4:5, pages 537-547.
Read now
Read now
John M Kovarik & Pascale Burtin. (2003) Immunosuppressants in advanced clinical development for organ transplantation and selected autoimmune diseases. Expert Opinion on Emerging Drugs 8:1, pages 47-62.
Read now
Read now
Articles from other publishers (21)
F. Piehl. (2020) Current and emerging disease‐modulatory therapies and treatment targets for multiple sclerosis. Journal of Internal Medicine 289:6, pages 771-791.
Crossref
Crossref
Jacqueline Palace, Martin Duddy, Thomas Bregenzer, Michael Lawton, Feng Zhu, Mike Boggild, Benjamin Piske, Neil P Robertson, Joel Oger, Helen Tremlett, Kate Tilling, Yoav Ben-Shlomo & Charles Dobson. (2015) Effectiveness and cost-effectiveness of interferon beta and glatiramer acetate in the UK Multiple Sclerosis Risk Sharing Scheme at 6 years: a clinical cohort study with natural history comparator. The Lancet Neurology 14:5, pages 497-505.
Crossref
Crossref
Emily J. Hadgkiss, George A. Jelinek, Tracey J. Weiland, Greg Rumbold, Claire A. Mackinlay, Siegfried Gutbrod & Ian Gawler. (2012) Health-related quality of life outcomes at 1 and 5 years after a residential retreat promoting lifestyle modification for people with multiple sclerosis. Neurological Sciences 34:2, pages 187-195.
Crossref
Crossref
Saravanan Kanakasabai, Eli Casalini, Crystal C. Walline, Caiqing Mo, Wanida Chearwae & John J. Bright. (2012) Differential regulation of CD4+ T helper cell responses by curcumin in experimental autoimmune encephalomyelitis. The Journal of Nutritional Biochemistry 23:11, pages 1498-1507.
Crossref
Crossref
Carlo TornatoreJ. Theodore PhillipsOmar KhanAaron E. MillerChristopher J. Barnes. (2012) Practice patterns of US neurologists in patients with CIS, RRMS, or RIS. Neurology Clinical Practice 2:1, pages 48-57.
Crossref
Crossref
DJ Rigotti, A Gass, L Achtnichts, M Inglese, JS Babb, Y Naegelin, J Hirsch, M Amann, L Kappos & O Gonen. (2011)
Multiple Sclerosis Severity Scale and whole-brain
N
-acetylaspartate concentration for patients’ assessment
. Multiple Sclerosis Journal 18:1, pages 98-107.
Crossref
Crossref
David Yamamoto & Jonathan D. Campbell. (2012) Cost-Effectiveness of Multiple Sclerosis Disease-Modifying Therapies: A Systematic Review of the Literature. Autoimmune Diseases 2012, pages 1-13.
Crossref
Crossref
Jessica Sharac, Paul McCrone & Ramon Sabes-Figuera. (2010) Pharmacoeconomic Considerations in the Treatment of Multiple Sclerosis. Drugs 70:13, pages 1677-1691.
Crossref
Crossref
Hanna M Vesterinen, Emily S Sena, Charles ffrench-Constant, Anna Williams, Siddharthan Chandran & Malcolm R Macleod. (2010) Improving the translational hit of experimental treatments in multiple sclerosis. Multiple Sclerosis Journal 16:9, pages 1044-1055.
Crossref
Crossref
Slobodan JankovicM.M., Marina Kostic, Marija Radosavljevic, Danka Tesic, Natasa Stefanovic-Stoimenov, Ivan Stevanovic, Sladjana Rakovic, Jelena Aleksic, Marko Folic, Aleksandra Aleksic, Ivana Mihajlovic, Nenad Biorac, Jelena Borlja & Radosava Vuckovic. (2009) Cost-effectiveness of four immunomodulatory therapies for relapsingremitting multiple sclerosis: A Markov model based on data a Balkan country in socioeconomic transition. Vojnosanitetski pregled Military Medical and Pharmaceutical Journal of Serbia 66:7, pages 556-562.
Crossref
Crossref
G. Mosayebi, A. Ghazavi, H. Salehi, M.A. Payani & M.R. Khazaei. (2007) Effect of Sesame Oil on the Inhibition of Experimental Autoimmune Encephalomyelitis in C57BL/6 Mice. Pakistan Journal of Biological Sciences 10:11, pages 1790-1796.
Crossref
Crossref
Julie A Brousil, Russel J Roberts & Amanda L Schlein. (2016) Cladribine: An Investigational Immunomodulatory Agent for Multiple Sclerosis. Annals of Pharmacotherapy 40:10, pages 1814-1821.
Crossref
Crossref
Gladson Muthian, Himanshu P. Raikwar, Johnson Rajasingh & John J. Bright. (2006) 1,25 dihydroxyvitamin-D3 modulates JAK–STAT pathway in IL-12/IFNγ axis leading to Th1 response in experimental allergic encephalomyelitis. Journal of Neuroscience Research 83:7, pages 1299-1309.
Crossref
Crossref
. 2006. McAlpine's Multiple Sclerosis. McAlpine's Multiple Sclerosis
811
946
.
Gladson Muthian, Himanshu P. Raikwar, Caroline Johnson, Johnson Rajasingh, Amit Kalgutkar, Lawrence J. Marnett & John J. Bright. (2006) COX-2 Inhibitors Modulate IL-12 Signaling Through JAK-STAT Pathway Leading to Th1 Response in Experimental Allergic Encephalomyelitis. Journal of Clinical Immunology 26:1, pages 73-85.
Crossref
Crossref
Ronald J. Ozminkowski, William D. Marder, Kevin Hawkins, Shaohung Wang, Sarah C. Stallings, Stan N. Finkelstein, Anthony J. Sinskey & David Wierz. (2004) The use of disease-modifying new drugs for multiple sclerosis treatment in private-sector health plans. Clinical Therapeutics 26:8, pages 1341-1354.
Crossref
Crossref
Peter Flachenecker & Peter Rieckmann. (2004) Health outcomes in multiple sclerosis. Current Opinion in Neurology 17:3, pages 257-261.
Crossref
Crossref
Ceri J Phillips. (2004) The Cost of Multiple Sclerosis and the Cost Effectiveness of Disease-Modifying Agents in its Treatment. CNS Drugs 18:9, pages 561-574.
Crossref
Crossref
A.B. Siddique & D. Wright. (2003) Effects of Time of Harvest at Different Moisture Contents on Seed Fresh Weight, Dry Weight, Quality (Viability and Vigour) and Food Reserves of Peas (Pisum sativum L.). Asian Journal of Plant Sciences 2:13, pages 983-992.
Crossref
Crossref
Chandramohan Natarajan & John J. Bright. (2002) Curcumin Inhibits Experimental Allergic Encephalomyelitis by Blocking IL-12 Signaling Through Janus Kinase-STAT Pathway in T Lymphocytes. The Journal of Immunology 168:12, pages 6506-6513.
Crossref
Crossref
C Natarajan & J J Bright. (2002) Peroxisome proliferator-activated receptor-gamma agonists inhibit experimental allergic encephalomyelitis by blocking IL-12 production, IL-12 signaling and Th1 differentiation. Genes & Immunity 3:2, pages 59-70.
Crossref
Crossref